Compare Stocks: CAPR, ADMA, ZBIO, and AUPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.23 -1.7%	$9.23	$7.21 ▼ $20.46	$2.07B	0.78	1.71 million shs	2.27 million shs
AUPH Aurinia Pharmaceuticals	$16.10 -0.1%	$15.81	$10.34 ▼ $19.25	$2.14B	1.4	895,977 shs	745,434 shs
CAPR Capricor Therapeutics	$8.37 +0.8%	$11.05	$2.96 ▼ $40.37	$486.62M	0.72	10.86 million shs	2.07 million shs
ZBIO Zenas BioPharma	$31.12 +0.1%	$31.16	$13.50 ▼ $44.60	$2.03B	-1.04	674,395 shs	421,698 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-4.05%	-1.91%	+12.42%	-41.43%
AUPH Aurinia Pharmaceuticals	0.00%	+0.12%	+6.06%	+1.77%	+31.75%
CAPR Capricor Therapeutics	0.00%	-10.96%	+98.81%	-67.56%	+32.23%
ZBIO Zenas BioPharma	0.00%	-5.35%	+6.58%	+57.17%	+57.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.23 -1.7%	$9.23	$7.21 ▼ $20.46	$2.07B	0.78	1.71 million shs	2.27 million shs
AUPH Aurinia Pharmaceuticals	$16.10 -0.1%	$15.81	$10.34 ▼ $19.25	$2.14B	1.4	895,977 shs	745,434 shs
CAPR Capricor Therapeutics	$8.37 +0.8%	$11.05	$2.96 ▼ $40.37	$486.62M	0.72	10.86 million shs	2.07 million shs
ZBIO Zenas BioPharma	$31.12 +0.1%	$31.16	$13.50 ▼ $44.60	$2.03B	-1.04	674,395 shs	421,698 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-4.05%	-1.91%	+12.42%	-41.43%
AUPH Aurinia Pharmaceuticals	0.00%	+0.12%	+6.06%	+1.77%	+31.75%
CAPR Capricor Therapeutics	0.00%	-10.96%	+98.81%	-67.56%	+32.23%
ZBIO Zenas BioPharma	0.00%	-5.35%	+6.58%	+57.17%	+57.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	102.24% Upside
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	9.73% Upside
CAPR Capricor Therapeutics	2.18	Hold	$29.15	248.27% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$45.71	46.90% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, ZBIO, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $32.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/14/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
8/14/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.05	$0.65 per share	14.11	$2.01 per share	4.59
AUPH Aurinia Pharmaceuticals	$283.05M	7.57	$1.01 per share	15.89	$4.41 per share	3.65
CAPR Capricor Therapeutics	$22.27M	21.85	N/A	N/A	$5.53 per share	1.51
ZBIO Zenas BioPharma	$10M	202.84	N/A	N/A	$4.51 per share	6.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.19	10.86	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.03	18.72	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	11/12/2026 (Estimated)

Latest CAPR, ADMA, ZBIO, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/12/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
CAPR Capricor Therapeutics	N/A	7.35	7.35
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AUPH Aurinia Pharmaceuticals	36.83%
CAPR Capricor Therapeutics	21.68%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
AUPH Aurinia Pharmaceuticals	10.40%
CAPR Capricor Therapeutics	9.20%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
AUPH Aurinia Pharmaceuticals	128	133.05 million	119.21 million	Optionable
CAPR Capricor Therapeutics	101	58.14 million	52.79 million	Optionable
ZBIO Zenas BioPharma	167	65.18 million	50.84 million	N/A

CAPR, ADMA, ZBIO, and AUPH Headlines

Recent News About These Companies

Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Bank of New York Mellon Corp Invests $1.79 Million in Zenas BioPharma, Inc. $ZBIO

September 9, 2026 | marketbeat.com

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

September 8, 2026 | globenewswire.com

Wellington Management Group LLP Has $40.45 Million Stock Holdings in Zenas BioPharma, Inc. $ZBIO

September 5, 2026 | marketbeat.com

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

September 4, 2026 | globenewswire.com

BlackRock Inc. Acquires New Shares in Zenas BioPharma, Inc. $ZBIO

August 31, 2026 | marketbeat.com

J. Goldman & Co LP Acquires New Position in Zenas BioPharma, Inc. $ZBIO

August 26, 2026 | marketbeat.com

Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO

August 26, 2026 | marketbeat.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Brokerages

August 23, 2026 | marketbeat.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2026 | globenewswire.com

HC Wainwright Predicts Higher Earnings for Zenas BioPharma

August 18, 2026 | marketbeat.com

Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO

August 15, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

August 14, 2026 | marketbeat.com

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

August 14, 2026 | marketbeat.com

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

July 14, 2026 | seekingalpha.com

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

July 11, 2026 | finance.yahoo.com

Zenas BioPharma Inc ZBIO

June 27, 2026 | morningstar.comM

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

June 24, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAPR, ADMA, ZBIO, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.23 -0.16 (-1.70%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$9.28 +0.05 (+0.50%)

As of 09/11/2026 07:30 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.10 -0.01 (-0.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$16.17 +0.07 (+0.45%)

As of 09/11/2026 07:55 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Capricor Therapeutics NASDAQ:CAPR

$8.37 +0.07 (+0.84%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.40 +0.03 (+0.36%)

As of 09/11/2026 07:53 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Zenas BioPharma NASDAQ:ZBIO

$31.12 +0.02 (+0.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$31.14 +0.02 (+0.05%)

As of 09/11/2026 07:30 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, ZBIO, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ADMA, ZBIO, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ADMA, ZBIO, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ADMA, ZBIO, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

Aurinia Pharmaceuticals NASDAQ:AUPH

Capricor Therapeutics NASDAQ:CAPR

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ADMA, ZBIO, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ADMA, ZBIO, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ADMA, ZBIO, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CAPR, ADMA, ZBIO, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

Aurinia Pharmaceuticals NASDAQ:AUPH

Capricor Therapeutics NASDAQ:CAPR

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools